These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
99 related articles for article (PubMed ID: 20181485)
1. Synthesis, radiofluorination, and hypoxia-selective studies of FRAZ: A configurational and positional analogue of the clinical hypoxia marker, [18F]-FAZA. Kumar P; Naimi E; McEwan AJ; Wiebe LI Bioorg Med Chem; 2010 Mar; 18(6):2255-2264. PubMed ID: 20181485 [TBL] [Abstract][Full Text] [Related]
2. Synthesis of [ Sun W; Falzon C; Naimi E; Akbari A; Wiebe LI; Tandon M; Kumar P Curr Radiopharm; 2019; 12(1):49-57. PubMed ID: 30338747 [TBL] [Abstract][Full Text] [Related]
10. A limited overlap between intratumoral distribution of 1-(5-fluoro-5-deoxy-α-D-arabinofuranosyl)-2-nitroimidazole and copper-diacetyl-bis[N(4)-methylthiosemicarbazone]. Furukawa T; Yuan Q; Jin ZH; Aung W; Yoshii Y; Hasegawa S; Endo H; Inoue M; Zhang MR; Fujibayashi Y; Saga T Oncol Rep; 2015 Sep; 34(3):1379-87. PubMed ID: 26134305 [TBL] [Abstract][Full Text] [Related]
11. Simple, column purification technique for the fully automated radiosynthesis of [18F]fluoroazomycinarabinoside ([18F]FAZA). Nandy SK; Rajan MG Appl Radiat Isot; 2010 Oct; 68(10):1944-9. PubMed ID: 20478712 [TBL] [Abstract][Full Text] [Related]
12. Pretreatment 18F-FAZA PET predicts success of hypoxia-directed radiochemotherapy using tirapazamine. Beck R; Röper B; Carlsen JM; Huisman MC; Lebschi JA; Andratschke N; Picchio M; Souvatzoglou M; Machulla HJ; Piert M J Nucl Med; 2007 Jun; 48(6):973-80. PubMed ID: 17536108 [TBL] [Abstract][Full Text] [Related]
13. An enzymatic route to 5-deoxy-5-[18F]fluoro-D-ribose, a [18F]-fluorinated sugar for PET imaging. Onega M; Domarkas J; Deng H; Schweiger LF; Smith TA; Welch AE; Plisson C; Gee AD; O'Hagan D Chem Commun (Camb); 2010 Jan; 46(1):139-41. PubMed ID: 20024319 [TBL] [Abstract][Full Text] [Related]
14. Hypoxia-selective antitumor agents. 10. bis(nitroimidazoles) and related Bis(nitroheterocycles): development of derivatives with higher rates of metabolic activation under hypoxia and improved aqueous solubility. Hay MP; Lee HH; Wilson WR; Roberts PB; Denny WA J Med Chem; 1995 May; 38(11):1928-41. PubMed ID: 7783125 [TBL] [Abstract][Full Text] [Related]
15. Synthesis of new hypoxia markers EF1 and [18F]-EF1. Kachur AV; Dolbier WR; Evans SM; Shiue CY; Shiue GG; Skov KA; Baird IR; James BR; Li AR; Roche A; Koch CJ Appl Radiat Isot; 1999 Dec; 51(6):643-50. PubMed ID: 10581679 [TBL] [Abstract][Full Text] [Related]
16. Hypoxia imaging agents labeled with positron emitters. Hoigebazar L; Jeong JM Recent Results Cancer Res; 2013; 194():285-99. PubMed ID: 22918765 [TBL] [Abstract][Full Text] [Related]
17. High-yield automated synthesis of [18F]fluoroazomycin arabinoside ([18F]FAZA) for hypoxia-specific tumor imaging. Hayashi K; Furutsuka K; Takei M; Muto M; Nakao R; Aki H; Suzuki K; Fukumura T Appl Radiat Isot; 2011 Jul; 69(7):1007-13. PubMed ID: 21420304 [TBL] [Abstract][Full Text] [Related]
18. Synthesis, in vitro and in vivo characterization of two novel 68Ga-labelled 5-nitroimidazole derivatives as potential agents for imaging hypoxia. Fernández S; Dematteis S; Giglio J; Cerecetto H; Rey A Nucl Med Biol; 2013 Feb; 40(2):273-9. PubMed ID: 23218939 [TBL] [Abstract][Full Text] [Related]
19. Novel nitroimidazole alkylsulfonamides as hypoxic cell radiosensitisers. Bonnet M; Hong CR; Gu Y; Anderson RF; Wilson WR; Pruijn FB; Wang J; Hicks KO; Hay MP Bioorg Med Chem; 2014 Apr; 22(7):2123-32. PubMed ID: 24650701 [TBL] [Abstract][Full Text] [Related]